TOKENPOST
1 min read
Add as a preferred source on Google

SELLAS REGAL Trial Reaches 80th Death Event, Triggering Final Analysis

Topline primary-endpoint results from the Phase 3 trial are expected this quarter.

By John Kim
Published
An empty examination chair sits in a softly lit clinical room / TokenPost.ai
An empty examination chair sits in a softly lit clinical room / TokenPost.ai

SELLAS Life Sciences Group, Inc. said Oct. 28 that its Phase 3 REGAL trial of galinpepimut-S (GPS) in acute myeloid leukemia reached its prespecified 80th death event, triggering a final analysis.

Topline results for the trial’s primary endpoint are expected this quarter.

John Kim

John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

Loading…